Last reviewed · How we verify
Simvastatin-Methylcellulose
Simvastatin inhibits HMG-CoA reductase to lower cholesterol, while methylcellulose acts as a solubility enhancer and sustained-release excipient to improve drug bioavailability.
Simvastatin inhibits HMG-CoA reductase to lower cholesterol, while methylcellulose acts as a solubility enhancer and sustained-release excipient to improve drug bioavailability. Used for Hypercholesterolemia and dyslipidemia, Cardiovascular disease prevention.
At a glance
| Generic name | Simvastatin-Methylcellulose |
|---|---|
| Also known as | Simvastatin |
| Sponsor | University of Nebraska |
| Drug class | HMG-CoA reductase inhibitor (statin) |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Simvastatin is a statin that competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol and triglycerides. Methylcellulose is a cellulose derivative used as a pharmaceutical excipient to enhance drug dissolution, provide sustained release, and improve gastrointestinal tolerability of the active ingredient.
Approved indications
- Hypercholesterolemia and dyslipidemia
- Cardiovascular disease prevention
Common side effects
- Myalgia
- Elevated liver enzymes
- Headache
- Gastrointestinal disturbance
Key clinical trials
- Effect of Locally Applied Simvastatin Gel on Dental Implant Stability and Marginal Bone Level (NA)
- Effect of Locally-Applied Simvastatin on Clinical Attachment Level and Alveolar Bone in Periodontal Maintenance Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |